Veterans Affairs Canada

Helmets to Hardhats working to increase female representation in the skilled trades

Retrieved on: 
Friday, March 8, 2024
Well, International, Woman, Construction, Time management, Helmet, Indigenous peoples, Ageing, H2H, Workforce, Veterans Affairs Canada, Veteran, Partnership, Management

Helmets to Hardhats is undertaking this work with the support of the Office to Advance Women Apprentices (OAWA).

Key Points: 
  • Helmets to Hardhats is undertaking this work with the support of the Office to Advance Women Apprentices (OAWA).
  • Helmets to Hardhats expects to surpass their goal of 150 diverse registrants by the end of March 2024.
  • While Helmets to Hardhats fills career vacancies with trained, skilled, and reliable employees, they also aid in the successful transition, financial stability, and increased visibility of underrepresented groups within the skilled trades.
  • At Helmets to Hardhats, I can promote and connect other Veterans to incredible and versatile careers in the skilled trades.

Minister Petitpas Taylor to bring Veterans, women Veterans and stakeholders together for a week of engagement

Retrieved on: 
Thursday, February 15, 2024
Woman, The Honourable, Life, Health, Minister, Hearing, Veterans' affairs, International Women's Day, Veterans Affairs Canada

During March 5-8, Minister Petitpas Taylor will host two events in Montreal, the National Stakeholder Summit and the Women Veterans Forum.

Key Points: 
  • During March 5-8, Minister Petitpas Taylor will host two events in Montreal, the National Stakeholder Summit and the Women Veterans Forum.
  • The National Stakeholder Summit and the Women Veterans Forum present a valued opportunity to listen and learn from Veterans and women Veterans to better help shape their future."
  • As women currently represent 16 percent of the Canadian Armed Forces, Veterans Affairs Canada continues work to support women Veterans by collaborating with researchers, partner organizations and women Veterans themselves.
  • Women Veterans have been engaged at the 2019 Women Veterans Forum, the 2020 Women and 2SLGBTQI+ Veterans virtual series, and the 2023 Women and 2SLGBTQI+ Forum.

MITSUBISHI TANABE PHARMA CANADA ANNOUNCES ORAL TREATMENT FORMULATION FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) NOW ELIGIBLE FOR COVERAGE THROUGH VETERAN AFFAIRS CANADA AND INDIGENOUS SERVICES CANADA

Retrieved on: 
Wednesday, December 13, 2023
Health Canada, Brain, VAC, Indigenous Services Canada, ALS Society of Canada, ALS, MTPA, MTP, ALS2, Veterans Affairs Canada, Edaravone, Diagnosis, Pharmaceutical industry, Labrador

TORONTO, Dec. 13, 2023 /CNW/ - Mitsubishi Tanabe Pharma Canada (MTP-CA) a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® Oral Suspension (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive, neurodegenerative disease1, is now reimbursed by Veterans Affairs Canada (VAC) (Standard Benefit) and Indigenous Services Canada via the Non-Insured Health Benefits (NIHB) Program (Limited Use).

Key Points: 
  • TORONTO, Dec. 13, 2023 /CNW/ - Mitsubishi Tanabe Pharma Canada (MTP-CA) a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® Oral Suspension (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive, neurodegenerative disease1, is now reimbursed by Veterans Affairs Canada (VAC) (Standard Benefit) and Indigenous Services Canada via the Non-Insured Health Benefits (NIHB) Program (Limited Use).
  • "We would like to thank Veterans Affairs Canada and Indigenous Services Canada for providing eligible people in Canada with access to this new ALS treatment formulation," said Andrew Zylak, President, MTP-CA.
  • "Including RADICAVA® Oral Suspension on these formularies is an important step to support those living with ALS who are eligible under the federal programs."
  • To date, it is estimated that the majority of private insurance plans in the country cover RADICAVA® Oral Suspension.

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

Retrieved on: 
Thursday, November 9, 2023
Knowledge, Post-traumatic stress disorder, University of Calgary, MDMA, Veterans Affairs Canada, UC, Physician, OTC, Health Canada, Ethics, Special access program, Party, Research, RWE, CSE, Trauma, Nature, PTSD, Trial, Real, Clinical trial, Partnership, SAP, University, LOI, GMP, Safety, Collection, Patient, DSM-IV codes, Mental health, Senate, Pharmaceutical industry, Veteran

The University of Calgary, under the direction of Dr. Leah Mayo, Parker Research Chair in Psychedelics, will assess data pertaining to efficacy of MDMA in the treatment of PTSD under real-world circumstances.

Key Points: 
  • The University of Calgary, under the direction of Dr. Leah Mayo, Parker Research Chair in Psychedelics, will assess data pertaining to efficacy of MDMA in the treatment of PTSD under real-world circumstances.
  • This trial will generate Real World Evidence (“RWE”) on the efficacy of MDMA in the treatment of Post-Traumatic Stress Disorder which may be submitted to Health regulators, including Health Canada and Veterans Affairs Canada.
  • As the trial is Observational in nature, no patients will be dosed as part of the trial’s protocol.
  • The goal of the trial is to gather data on the efficacy of treatment for patients who are already qualified for treatment under the Special Access Program.

Canadian Psychedelic Trade Association Endorses Senate Report Calling for Research into Psychedelic-Assisted Therapy

Retrieved on: 
Wednesday, November 8, 2023
Psilocybin, Science, Government, Post-traumatic stress disorder, Parliament, Anxiety, MDMA, Veterans Affairs Canada, MDD, Chronic pain, Public, DND, Treatment, Health Canada, Veteran, Government of Canada, Doctor of Philosophy, Research, National security, Equitable Access to Care and Health Act, Canadian Institutes of Health Research, PTSD, OUD, CIHR, Atypical depression, DSM-IV codes, AUD, Partnership, VAC, TUD, House, Safety, Nicotine, Veterans' affairs, TRD, Mental health, Senate, Pharmaceutical industry, Nursing

OTTAWA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — enthusiastically endorses a new report by the Senate of Canada Subcommittee on Veteran Affairs urging federal, provincial, and territorial governments to launch and fund a large-scale research program into psychedelic-assisted therapy.

Key Points: 
  • OTTAWA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PsyCan — the not-for-profit trade association of legally-operating Canadian psychedelic companies — enthusiastically endorses a new report by the Senate of Canada Subcommittee on Veteran Affairs urging federal, provincial, and territorial governments to launch and fund a large-scale research program into psychedelic-assisted therapy.
  • While Canada is a leader in developing these innovative treatments, many barriers remain to patient access, and government must play an active role.
  • “This report echoes our calls for government funding into psychedelic-assisted therapy,” said PharmAla Biotech CEO and PsyCan Chair Nick Kadysh.
  • “Research on these subjects is constantly evolving and will continue to do so.

MITSUBISHI TANABE PHARMA CANADA ANNOUNCES THAT COMPANY'S ORAL TREATMENT FORMULATION FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) HAS BEEN ADDED TO THE PROVINCIAL DRUG PLANS IN PRINCE EDWARD ISLAND, NEWFOUNDLAND AND LABRADOR

Retrieved on: 
Tuesday, November 7, 2023
Government, MTPA, Veterans Affairs Canada, PEI, ALS, Life, Indigenous Services Canada, Neurology, Health Canada, Face, News, ALS Society of Canada, Disease, Pharmacare, Memorial University of Newfoundland, Brain, Patient, Diagnosis, Edaravone, Pharmaceutical industry, Health insurance, Dentistry

"To date, RADICAVA® Oral Suspension is listed on the majority of provincial public drug plans.

Key Points: 
  • "To date, RADICAVA® Oral Suspension is listed on the majority of provincial public drug plans.
  • MTP-CA will continue to work with the remaining provincial, territorial and federal drug plans to help ensure that RADICAVA® Oral Suspension is listed on all public formularies across the country."
  • To date, it is estimated that the majority of private insurance plans in the country cover RADICAVA® Oral Suspension.
  • MTP-CA continues to have discussions with the territories and federal agencies regarding the listing of RADICAVA® Oral Suspension under additional publicly funded drug programs.

Public reimbursement for biosimilar BYOOVIZ™ to treat serious retinal disorders now secured in four provinces and two national benefits programs

Retrieved on: 
Wednesday, October 4, 2023
Retina, VAC, Anti-VEGF, AMD, Diabetic retinopathy, Patient, Physician, Veterans Affairs Canada, Ranibizumab, Safety, Health insurance

In addition, BYOOVIZ is now covered by the Non-Insured Health Benefits (NIHB) and Veterans Affairs Canada (VAC) Health Care Benefits programs.

Key Points: 
  • In addition, BYOOVIZ is now covered by the Non-Insured Health Benefits (NIHB) and Veterans Affairs Canada (VAC) Health Care Benefits programs.
  • BYOOVIZ is the first biosimilar available in Canada that references PrLUCENTIS® to treat retinal vascular disorders including neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema.
  • This provides an additional option for retinal disease management with anti-VEGF therapies, which have become a therapeutic mainstay for various retinal vascular disorders1.
  • Public reimbursement of biosimilars helps create opportunities for savings and resource reallocation to other areas in the healthcare system.

MITSUBISHI TANABE PHARMA CANADA ANNOUNCES THAT COMPANY'S ORAL TREATMENT FORMULATION FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) HAS BEEN ADDED TO THE PROVINCIAL DRUG PLANS IN NEW BRUNSWICK AND NOVA SCOTIA

Retrieved on: 
Tuesday, August 29, 2023
Indigenous Services Canada, Life, Face, Edaravone, Neurodegenerative disease, ALS Society of Canada, Brain, Physical medicine and rehabilitation, MTPA, Rehabilitation, Patient, Dalhousie University, Veterans Affairs Canada, Diagnosis, Health Canada, ALS, News, Disease, Pharmaceutical industry, Health insurance, Atlantic Ocean

"We will continue to collaborate with decision makers to help ensure that RADICAVA® Oral Suspension is made available through all publicly funded drug plans."

Key Points: 
  • "We will continue to collaborate with decision makers to help ensure that RADICAVA® Oral Suspension is made available through all publicly funded drug plans."
  • In addition to New Brunswick and Nova Scotia, RADICAVA® Oral Suspension is also listed on the public drug plans in Ontario, Alberta, Québec and British Columbia.
  • To date, it is estimated that the majority of private insurance plans in the country cover RADICAVA® Oral Suspension.
  • MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA® Oral Suspension under additional publicly funded drug programs.

MITSUBISHI TANABE PHARMA CANADA ANNOUNCES THAT COMPANY'S ORAL TREATMENT FORMULATION FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) HAS BEEN ADDED TO THE PROVINCIAL DRUG PLAN IN ONTARIO

Retrieved on: 
Tuesday, August 1, 2023
Indigenous Services Canada, Mitsubishi Tanabe Pharma, ALS Society of Canada, Edaravone, PCPA, Spinal cord, Eating, MTP, Pan-Canadian Pharmaceutical Alliance, Brain, Government, Brain cell, MTPA, Walking, Physician, Veterans Affairs Canada, Diagnosis, FRCPC, Health Canada, ALS, Sunnybrook Health Sciences Centre, News, Community Access Program, Health insurance, Dentistry

RADICAVA® Oral Suspension was authorized by Health Canada on November 8, 2022.

Key Points: 
  • RADICAVA® Oral Suspension was authorized by Health Canada on November 8, 2022.
  • To date, it is estimated that the majority of private insurance plans in the country cover RADICAVA® Oral Suspension.
  • MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA® Oral Suspension under additional publicly funded drug programs.
  • The reimbursement criteria for RADICAVA® Oral Suspension are the same as for RADICAVA® IV, which can be found on the Ontario Ministry of Health's Exceptional Access Program webpage.

Dimensions Announces Ground-breaking Therapeutic Program for Veterans

Retrieved on: 
Wednesday, June 7, 2023
Yoga, IDC, Dimension, Central nervous system, VAC, Depression, Timeline of cannabis laws in the United States, FRCS, Post-traumatic stress disorder, Anxiety, Psychotherapy, Acute stress disorder, Emotion, PTSI, CND4, Doctor of Philosophy, RP, Meal, DesignAge, Nature, Nervous system, Neuroscience, Veterans Affairs Canada, Haliburton/Stanhope Municipal Airport, Injury, Health, Trauma, PTSD, Nursing, Veteran

TORONTO, June 07, 2023 (GLOBE NEWSWIRE) -- Dimensions , has announced that Veterans Affairs Canada (VAC) has officially approved their ELEVATE for Veterans-Only Program as a VAC Interdisciplinary (IDC) inpatient program.

Key Points: 
  • TORONTO, June 07, 2023 (GLOBE NEWSWIRE) -- Dimensions , has announced that Veterans Affairs Canada (VAC) has officially approved their ELEVATE for Veterans-Only Program as a VAC Interdisciplinary (IDC) inpatient program.
  • The Canadian company offers health and wellness retreat experiences with a therapeutic focus on mental health disorders affecting the central nervous system.
  • “Dimensions’ IDC designation by VAC signals a positive complement or alternative to traditional cognitive and talk therapies.
  • “We recognize their contributions, and we are grateful to this group who have helped shape the program on behalf of their fellow Veterans,” commented Donald Currie, RP, Clinical Director, Dimensions Algonquin Highlands.